Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

RM Materials - Reference Articles for Molecular Oncology

  1. RA MacLeod, S Nagel, M Scherr, B Schneider, WG Dirks, CC Uphoff, H Quentmeier, HG Drexler (2008). Human leukemia and lymphoma cell lines as models and resources. Curr Med Chem 15(4):339-359.
  2. MR Gerstenblith, AM Goldstein, MA Tucker, MC Fraser (2008), Genetic testing for melanoma predisposition: current challenges. Cancer Nurs 30(6):452-459.
  3. J Saldanha, M Silvy, N Beaufils, R Arlinghaus, G Barbany, S Branford, JM Cayuela, G Cazzaniga, M Gonzalez, D Grimwade, V Kairisto, K Miyamura, M Lawler, T Lion, E Macintyre, FX Mahon, MC Muller, M Ostergaard, H Pfeifer, G Saglio, C Sawyers, O Spinelli, VH van der Velden, JQ Wang, K Zoi, V Patel, P Phillips, P Matejtschuk, J Gabert (2007). Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 21(7):1481-1487.
  4. R Yao & E Schneider (2007), Detection of B- and T-cell-specific gene rearrangements in 13 cell lines and 50 clinical specimens using the BIOMED-2 and the original InVivoScribe primers. Leukemia & Lymphoma 48(4):837-840.
  5. RL Levine et al. (2007), Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Reviews Cancer 7:673-683.
  6. H Quentmeier, RA MacLeod, M Zaborski, HG Drexler (2006). JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 20(3):471-476.
  7. O Ikediobi et al (2006), Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5(11):2606-2612.
  8. K Inokuchi (2006), Chronic Myelogenous Leukemia: from molecular biology to clinical aspects and novel targeted therapies. Nippon Med Sch 73(4):178-192.
  9. R Ren (2005), Mechanisms of BCR-ABL in the pathogenesis of Chronic Myelogenous Leukemia. Nat Reviews Cancer 5:172-183.
  10. B Messahel et al. (2005), Clinical features of molecular pathology of solid tumours in childhood. Lancet Oncol 6:421-430.
  11. B Chen et al. (2005), Developing a sustainable process to provide quality control materials for genetic testing. Genet Med 7(8):543-49.
  12. B Sunar-Reeder, DH Atha, S Aydemir, DJ Reeder, L Tully, AR Khan, CD O’Connell (2004). Use of TP53 reference materials to validate mutations in clinical tissue specimens by single-stranded conformational polymorphism analysis. Mol Diagn 8(2):123-130.
  13. HG Drexler, WG Dirks, Y Matsuo, RA MacLeod (2003). False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia 17(2):416-246.
  14. R Kurzrock et al. (2003), Philadelphia chromosome—positive Leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138:819-830.
  15. JJM van Dongen et al. (2003), Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257-2317.
  16. DL Stirewalt & JP Radich (2003), The role of FLT3 in haematopoietic malignancies. Nat Reviews Cancer 3:650-665.
  17. R Yao, SA Rich, & E Schneider (2002), Validation of sixteen Leukemia and Lymphoma cell lines as controls for molecular gene rearrangement assays. Clin Chem 48(8):1344-1351.
  18. S Pelengaris, M Khan, & G Evan (2002), c-MYC: more than just a matter of life and death. Nat Reviews Cancer 2:764-776.
  19. HG Drexler et al. (2000), Continuous hematopoietic cell lines as model systems for Leukemia-Lymphoma research. Leukemia Res 24:881-911.
  20. JE Rubnitz & WM Crist (1997), Molecular genetics of childhood cancer: implications for pathogenesis, diagnosis, and treatment. Pediatrics 100:101-108.